Terms: = Germ cell tumor AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Prognosis
1112 results:
1. A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.
Du Z; Jiang Y; Yang Y; Kang X; Yan J; Liu B; Yang M
Sci Rep; 2024 Apr; 14(1):9427. PubMed ID: 38658591
[TBL] [Abstract] [Full Text] [Related]
2. DKK3 Expression in Glioblastoma: Correlations with Biomolecular Markers.
Caffo M; Casili G; Caruso G; Barresi V; Campolo M; Paterniti I; Minutoli L; Ius T; Esposito E
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612910
[TBL] [Abstract] [Full Text] [Related]
3. IQGAP3 promotes the progression of glioma as an immune and prognostic marker.
Gao X; Ge J; Gao X; Mei NA; Su Y; Shan S; Qian W; Guan J; Zhang Z; Wang L
Oncol Res; 2024; 32(4):659-678. PubMed ID: 38560572
[No Abstract] [Full Text] [Related]
4. Focused ultrasound-mediated blood-brain barrier opening is safe and feasible with moderately hypofractionated radiotherapy for brainstem diffuse midline glioma.
Tazhibi M; McQuillan N; Wei HJ; Gallitto M; Bendau E; Webster Carrion A; Berg X; Kokossis D; Zhang X; Zhang Z; Jan CI; Mintz A; Gartrell RD; Syed HR; Fonseca A; Pavisic J; Szalontay L; Konofagou EE; Zacharoulis S; Wu CC
J Transl Med; 2024 Mar; 22(1):320. PubMed ID: 38555449
[TBL] [Abstract] [Full Text] [Related]
5. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract] [Full Text] [Related]
6. p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme.
Meng J; Qian W; Yang Z; Gong L; Xu D; Huang H; Jiang X; Pu Z; Yin Y; Zou J
BMC Cancer; 2024 Mar; 24(1):317. PubMed ID: 38454344
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study.
Miele E; Anghileri E; Calatozzolo C; Lazzarini E; Patrizi S; Ciolfi A; Pedace L; Patanè M; Abballe L; Paterra R; Maddaloni L; Barresi S; Mastronuzzi A; Petruzzi A; Tramacere I; Farinotti M; Gurrieri L; Pirola E; Scarpelli M; Lombardi G; Villani V; Simonelli M; Merli R; Salmaggi A; Tartaglia M; Silvani A; DiMeco F; Calistri D; Lamperti E; Locatelli F; Indraccolo S; Pollo B
Cancer Lett; 2024 Apr; 588():216711. PubMed ID: 38423245
[TBL] [Abstract] [Full Text] [Related]
8. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
Zhang W; Wang S
Melanoma Res; 2024 Jun; 34(3):215-224. PubMed ID: 38364052
[TBL] [Abstract] [Full Text] [Related]
9. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract] [Full Text] [Related]
10. Development and validation of a 23-gene expression signature for molecular subtyping of medulloblastoma in a long-term Chinese cohort.
Wang Y; Huang J; Yin X; Xu Q; Sun Y; Yao Y; Xiong J
Acta Neurochir (Wien); 2024 Feb; 166(1):72. PubMed ID: 38329556
[TBL] [Abstract] [Full Text] [Related]
11. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy.
Cordero-Hernandez IS; Ross AC; Dasari A; Halperin DM; Chasen B; Yao JC
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38329269
[TBL] [Abstract] [Full Text] [Related]
12. Molecular signature of stem-like glioma cells (SLGCs) from human glioblastoma and gliosarcoma.
Zechel C; Loy M; Wegner C; Dahlke E; Soetje B; Baehr L; Leppert J; Ostermaier JJ; Lueg T; Nielsen J; Elßner J; Willeke V; Marzahl S; Tronnier V; Madany Mamlouk A
PLoS One; 2024; 19(2):e0291368. PubMed ID: 38306361
[TBL] [Abstract] [Full Text] [Related]
13. Rise of oligodendroglioma hypermutator phenotype from a subclone harboring tp53 mutation after TMZ treatment.
Higuchi F; Uzuka T; Matsuda H; Sumi T; Iwata K; Namatame T; Shin M; Akutsu H; Ueki K
Brain Tumor Pathol; 2024 Apr; 41(2):80-84. PubMed ID: 38294664
[TBL] [Abstract] [Full Text] [Related]
14. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Liu S; Chai T; Garcia-Marques F; Yin Q; Hsu EC; Shen M; Shaw Toland AM; Bermudez A; Hartono AB; Massey CF; Lee CS; Zheng L; Baron M; Denning CJ; Aslan M; Nguyen HM; Nolley R; Zoubeidi A; Das M; Kunder CA; Howitt BE; Soh HT; Weissman IL; Liss MA; Chin AI; Brooks JD; Corey E; Pitteri SJ; Huang J; Stoyanova T
Cell Rep Med; 2024 Feb; 5(2):101381. PubMed ID: 38244540
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic and predictive biomarkers in paediatric solid tumours.
Glembocki AI; Somers GR
Pathology; 2024 Mar; 56(2):283-296. PubMed ID: 38216399
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study.
Deng L; Wang HY; Hu CF; Liu XY; Jiang K; Yong JJ; Wu XY; Guo KH; Wang F
Pigment Cell Melanoma Res; 2024 May; 37(3):363-371. PubMed ID: 38158377
[TBL] [Abstract] [Full Text] [Related]
17. Synergistic anti-proliferative and apoptotic effect of NVP-BEZ235 and curcumin on human SH-SY5Y neuroblastoma cells.
Çetin F; Kosba S; Abdik H; Bolat ZB
Med Oncol; 2023 Dec; 41(1):11. PubMed ID: 38071672
[TBL] [Abstract] [Full Text] [Related]
18. Clinical characteristics and prognostic factors of surgical treatment in children with brainstem tumor.
He YZ; Zhou Q; Deng WY; Huang LY; Lu YY; Ruan YY; Du H
Eur Rev Med Pharmacol Sci; 2023 Nov; 27(22):10926-10934. PubMed ID: 38039022
[TBL] [Abstract] [Full Text] [Related]
19. Optimal combination of MYCN differential gene and cellular senescence gene predicts adverse outcomes in patients with neuroblastoma.
Tan J; Wang C; Jin Y; Xia Y; Gong B; Zhao Q
Front Immunol; 2023; 14():1309138. PubMed ID: 38035110
[TBL] [Abstract] [Full Text] [Related]
20. The survivin-ran inhibitor LLP-3 decreases oxidative phosphorylation, glycolysis and growth of neuroblastoma cells.
Galiger C; Zohora FT; Dorneburg C; Tews D; Debatin KM; Beltinger C
BMC Cancer; 2023 Nov; 23(1):1148. PubMed ID: 38007466
[TBL] [Abstract] [Full Text] [Related]
[Next]